Rohtak News Magazine

Relapsed or Refractory Myelodysplastic Syndrome Market to Register Sustainable Growth During the Forecast Period – DelveInsight | Key Companies – Celgene, Celyad , Astex, Onconova, Agios Pharma

 Breaking News
  • No posts were found

Relapsed or Refractory Myelodysplastic Syndrome Market to Register Sustainable Growth During the Forecast Period – DelveInsight | Key Companies – Celgene, Celyad , Astex, Onconova, Agios Pharma

August 25
14:48 2022
Relapsed or Refractory Myelodysplastic Syndrome Market to Register Sustainable Growth During the Forecast Period - DelveInsight | Key Companies - Celgene, Celyad , Astex, Onconova, Agios Pharma
Delveinsight Business Research LLP
As per DelveInsight, the Relapsed or Refractory Myelodysplastic Syndrome Therapeutics Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, the increasing incident population in the 7MM, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.

DelveInsight’s “Relapsed or Refractory Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Relapsed or Refractory Myelodysplastic Syndrome Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Relapsed or Refractory Myelodysplastic Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Relapsed or Refractory Myelodysplastic Syndrome Market

Relapsed or Refractory Myelodysplastic Syndrome: An Overview

Myelodysplastic syndrome (MDS) constitutes a group of clonal myeloid neoplasms characterized by anemia or other cytopenias due to ineffective hematopoiesis, abnormal blood and bone marrow cell morphology, as well as the risk for clonal evolution and progression to acute myeloid leukemia (AML). Some patients have MDS cells in their bone marrow even after the treatment, which is called refractory MDS. While some patients have a return of MDS cells in the marrow and a decrease in normal blood cells after remission. This is called a relapse.

No standard exists for treating MDS relapsing after allogeneic stem cell transplantation.

Relapsed or Refractory Myelodysplastic Syndrome Market Key Facts

  • According to population-based registry data (1993–2008) analysis in Japan, the incidence of MDS sharply increased with age, particularly in those over age 70 years. The incidence in 65–69 years was reported to be 3.1 cases per 100,000 (men) and 1.1 cases per 100,000 (women), compared to 85 years, in which the rate was 17.7 and 8.9 cases per 100,000, respectively.

  • According to DelveInsight’s analysis, males are affected more than females in case of Relapsed or Refractory Myelodysplastic Syndrome (MDS).

  • As per the study by Zeidan et al., which included the retrospective examination of cancer registry data in the US, the age-adjusted incidence of MDS was 3.3 per 100,000 per year from 2001–2003 and 4.9 per year from 2007–2011. The annual age-adjusted incidence in the United States is approximately 4.0 per 100,000 persons. 

Relapsed or Refractory Myelodysplastic Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Relapsed or Refractory Myelodysplastic Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Relapsed or Refractory Myelodysplastic Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Relapsed or Refractory Myelodysplastic Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Relapsed or Refractory Myelodysplastic Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Relapsed or Refractory Myelodysplastic Syndrome market or expected to get launched during the study period. The analysis covers Relapsed or Refractory Myelodysplastic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Relapsed or Refractory Myelodysplastic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-market

Relapsed or Refractory Myelodysplastic Syndrome Therapeutics Analysis

Various companies are involved in developing effective therapies for Relapsed or Refractory Myelodysplastic Syndrome, and further progress in the research and development is likely to translate into real improvement in the treatment options for Relapsed or Refractory Myelodysplastic Syndrome in the coming years

Some of the Companies in the Relapsed or Refractory Myelodysplastic Syndrome Market include:

  • Celgene

  • Celyad 

  • Astex Pharmaceuticals

  • Onconova Therapeutics

  • Agios Pharmaceuticals

And many others

Relapsed or Refractory Myelodysplastic Syndrome Therapies covered in the report include:

  • Guadecitabine (SGI-110)

  • Rigosertib

  • CC-90009

  • TIBSOVO (ivosidenib)

  • CYAD-02

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Relapsed or Refractory Myelodysplastic Syndrome Competitive Intelligence Analysis

4. Relapsed or Refractory Myelodysplastic Syndrome Market Overview at a Glance

5. Relapsed or Refractory Myelodysplastic Syndrome Disease Background and Overview

6. Relapsed or Refractory Myelodysplastic Syndrome Patient Journey

7. Relapsed or Refractory Myelodysplastic Syndrome Epidemiology and Patient Population

8. Relapsed or Refractory Myelodysplastic Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Relapsed or Refractory Myelodysplastic Syndrome Unmet Needs

10. Key Endpoints of Relapsed or Refractory Myelodysplastic Syndrome Treatment

11. Relapsed or Refractory Myelodysplastic Syndrome Marketed Products

12. Relapsed or Refractory Myelodysplastic Syndrome Emerging Therapies

13. Relapsed or Refractory Myelodysplastic Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Relapsed or Refractory Myelodysplastic Syndrome Market Outlook (7 major markets)

16. Relapsed or Refractory Myelodysplastic Syndrome Access and Reimbursement Overview

17. KOL Views on the Relapsed or Refractory Myelodysplastic Syndrome Market.

18. Relapsed or Refractory Myelodysplastic Syndrome Market Drivers

19. Relapsed or Refractory Myelodysplastic Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-market

 

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Conductive Hearing Loss Market
“Conductive Hearing Loss Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Conductive Hearing Loss Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles